SCHEMBL20713853

SCHEMBL20713853

CCCCCCC(C)c1nnc(C)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.36
AKT1 P31749 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
GPR84 Q9NQS5 1/20 0.34
OPRM1 P35372 1/20 0.33
SPHK1 Q9NYA1 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
LMNA P02545 1/20 0.31
ADH1B P00325 1/20 0.31
ADH1C P00326 1/20 0.31
ADH1A P07327 1/20 0.31
ADH4 P08319 1/20 0.31
ADH7 P40394 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
DNM1 Q05193 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25488050 0.84 LMNA (0.36) ALDH1A1MAPTPOLBAKT1SMN1; SMN2
SCHEMBL19501167 0.79 KDM4E (0.40) POLBAKT1SMN1; SMN2LMNA
SCHEMBL21501800 0.73 POLB (0.37) ALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL19597509 0.70 GPR84 (0.36) SMN1; SMN2GPR84OPRM1SPHK1LMNA
SCHEMBL21115896 0.69 GLS (0.33) ALDH1A1MAPTLMNA
SCHEMBL23219755 0.69 GPR84 (0.38) GPR84OPRM1
SCHEMBL24608829 0.69 GPR84 (0.38) GPR84OPRM1
SCHEMBL19370495 0.68 NPC1 (0.41) GPR84NPC1RAB9A
SCHEMBL20630571 0.66 ALDH1A1 (0.37) ALDH1A1MAPTPOLBSMN1; SMN2TSHR
SCHEMBL20828428 0.66 KMT2A (0.46) ALDH1A1POLBSMN1; SMN2HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10544155-B2 Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-01-28 US disclosed
US-20190040076-A1 Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors MERCK SHARP & DOHME CORP. (US) 2019-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544155-B2 Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors NQO2, SIRT5, CCR5 ALDH1A1 704/4885MAPT 3508/4885POLB 515/4885
US-20190040076-A1 Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors NQO2, SIRT5, CCR5 ALDH1A1 704/4885MAPT 3508/4885POLB 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.